摘要
研究了成纤维细胞介导的ＩＬ－３基因疗法、ＩＬ－６基因疗法以及两者联合后对造血系统的影响。结果发现，单用ＩＬ－３基因疗法的小鼠白细胞总数、中性粒细胞、骨髓ＣＦＵ－ＧＭ、ＣＦＵ－ＭＫ等显著上升，但血小板上升程度软弱；单用ＩＬ－６基因疗法的小鼠血小板、中性粒细胞、骨髓ＣＦＵ－ＧＭ、ＣＦＵ－ＭＫ等显著上升，但白细胞总数上升不明显；当两者联合后可使血小板、中性粒细胞、骨髓ＣＦＵ－ＧＭ、ＣＦＵ－ＭＫ上升更为显著；且达高峰时间提前。表明联合应用成纤维细胞介导的ＩＬ－３基因疗法和ＩＬ－６基因疗法能比单一疗法更显著增强机体骨髓造血功能，使外周血细胞升高，从而为肿瘤患者放化疗后机体造血功能低下的治疗开辟了新的途径。
In the present study,investigated the effects of fibroblast-mediated interleukin-3(IL-3)gene therapy, interleukin-6(IL-6)gene therapy or their combination on the hematopoietic regulation. Had observed that IL-3 gene therapy could elevate the number of WBCs,neutrophils,CFU-GM and CFU-MK in bone marrow significantly,but had a little effect on plateletes. IL-6 gene therapy could elevate the number of plateletes,neutrophils,CFU-GM and CFU-MK in bone marrow significantly,but had little effect on WBCs. When IL-3 gene therapy was used in combination with IL-6 gene therapy,the number of plateletes,neutro phils,CFU-GM and CFU-MK was elevated in a most obvious way and reached the peak in advance. The results showed that fibroblast-mediated IL-3 gene therapy in combination with IL-6 gene therapy was more potent in the enhancement of hematopoietic functions than IL-3 gene therapy or IL-6 gene therapy alone. The data outline a new approach to treat chemotherapy-induced hematopoietic depress.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
1996年第6期366-369,共4页
Chinese Journal of Immunology
基金
国家自然科学基金优秀中青年人才专项基金
关键词
白细胞介素3
白细胞介素6
基因治疗
肿瘤
Interleukin-3 Interleukin-6 Gene therapy Fibroblast Hematopoiesis
